Information Update - Update: Certain lots of Elavil (amitriptyline) and APO-Amitriptyline recalled due to a nitrosamine impurity

·1 min read

MONTREAL, Jan. 25, 2022 /CNW/ - AA Pharma Inc. is recalling two lots of Elavil (amitriptyline) (lots PY1829 and PY1830) and Apotex Inc. is recalling one additional lot of APO-Amitriptyline (lot PY1832) 10 mg tablets due to the presence of NDMA, a nitrosamine impurity, above the acceptable limit. Patients can continue taking their amitriptyline drugs, as the risks from not having adequate treatment outweigh possible effects of exposure to the levels of NDMA seen in the recalled products. Patients do not need to return their medication to the pharmacy.

NDMA is classified as a probable human carcinogen. This means that long-term exposure to a level above what is considered safe may increase the risk of cancer. Health Canada is advising that there is no immediate risk in continuing to take the recalled APO-Amitriptyline or Elavil (amitriptyline) since the potential risk of cancer is with long-term exposure (every day for 70 years) to NDMA that exceeds safe levels.

Health Canada maintains a list of recalled amitriptyline drugs affected by this issue. Please see the full advisory for more information, including more on the risk and what patients should do.

Affected Products

Company

Product

Strength

DIN

Lot

Expiry

AA Pharma Inc.

Elavil

(Amitriptyline Hydrochloride
Tablets USP)

10 mg

00335053

PY1829

12/2023

AA Pharma Inc.

Elavil

(Amitriptyline Hydrochloride
Tablets USP)

10 mg

00335053

PY1830

12/2023

Apotex Inc.

APO-Amitriptyline

(Amitriptyline Hydrochloride
Tablets USP)

10 mg

02403137

PY1832

12/2023

Également disponible en français

SOURCE Health Canada

Cision
Cision

View original content: http://www.newswire.ca/en/releases/archive/January2022/26/c0505.html

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting